{"url_path":"/sec/abbv/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 OTHER ITEMS","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1551152/0001551152-26-000017-index.html","accession_number":"0001551152-26-000017","cik":"0001551152","ticker":"ABBV","issuer_name":"AbbVie Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1551152/0001551152-26-000017-index.html","primary_entity_key":"0001551152","primary_entity_name":"AbbVie Inc."},"word_count":55,"has_tables":true,"body_markdown":"ITEM 5. OTHER ITEMS\n\n(c) Director and Officer Trading Arrangements\n\nDuring the three months ended March 31, 2026, no director or officer of the company adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.\n\n2026 Form 10-Q |\n\n32"}